3,240
Views
12
CrossRef citations to date
0
Altmetric
Commentaries and Views

Hypothesis: AA amyloidosis is a factor causing systemic complications after coronavirus disease

ORCID Icon
Pages 53-55 | Received 16 Feb 2021, Accepted 26 Mar 2021, Published online: 20 Apr 2021

References

  • Machhi J, Herskovitz J, Senan AM, et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J Neuroimmune Pharmacol. 2020 Sep;15(3):359–386.
  • Dhakal BP, Sweitzer NK, Indik JH, et al. SARS-CoV-2 infection and cardiovascular disease: COVID-19 heart. Heart Lung Circ. 2020 Jul;29(7):973–987.
  • Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147.
  • Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020 Jul;18(7):1752–1755.
  • Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol. 2015;10:321–344.
  • Deshayes S, Aouba A, Grateau G, et al. Infections and AA amyloidosis: an overview. Int J Clin Pract. 2020 Dec;23:e13966.
  • Saha A, Theis JD, Vrana JA, et al. AA amyloidosis associated with hepatitis B. Nephrol Dial Transplant. 2011 Jul;26(7):2407–2412.
  • Sack GH Jr. Serum amyloid A - a review. Mol Med. 2018 Aug 30;24(1):46.
  • Borg J, Buttigieg J, Holwill S, et al. Treatment of renal AA-Amyloidosis associated with human immunodeficiency virus infection: a case report. CEN Case Rep. 2021 Feb;10(1):88–93.
  • Blank N, Lorenz HM. Diagnostik und Therapie der AA-Amyloidose [Diagnostics and therapy of AA amyloidosis]. Pathologe. 2009 May;30(3):219–225.
  • Srkalovic G, Cameron MG, Deitcher SR, et al. Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis. Int Semin Surg Oncol. 2005;2:17.
  • Liu SL, Wang SY, Sun YF, et al. Expressions of SAA, CRP, and FERR in different severities of COVID-19. Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11386–11394.
  • Tjendra Y, Al Mana AF, Espejo AP, et al. Predicting disease severity and outcome in COVID-19 patients: a review of multiple biomarkers. Arch Pathol Lab Med. 2020 Dec 1;144(12):1465–1474.
  • Chen M, Wu Y, Jia W, et al. The predictive value of serum amyloid A and C-reactive protein levels for the severity of coronavirus disease 2019. Am J Transl Res. 2020 Aug 15;12(8):4569–4575.
  • Haroun RA, Osman WH, Eessa AM. Interferon-γ-induced protein 10 (IP-10) and serum amyloid A (SAA) are excellent biomarkers for the prediction of COVID-19 progression and severity. Life Sci. 2021 Mar 15;269:119019.
  • Li H, Xiang X, Ren H, et al. Serum Amyloid A is a biomarker of severe Coronavirus disease and poor prognosis. J Infect. 2020 Jun;80(6):646–655.
  • Merlini G, Saraiva MJM, Sekijima Y, et al. Amyloid nomenclature 2018: recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2018 Dec;25(4):215–219.
  • Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2361–2371.
  • Nuvolone M, Merlini G. Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant. 2017 May 1;32(5):770–780.
  • Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin North Am. 2018 Nov;44(4):585–603.